LET + ACL Reconstruction for Knee Injuries
(STABILITY LTF Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether adding a procedure called lateral extra-articular tenodesis (LET) to standard ACL reconstruction affects long-term knee health, particularly the risk of developing osteoarthritis (OA). Researchers aim to determine if combining these treatments benefits or harms knees over time, using imaging and patient feedback. Individuals with a torn ACL who play competitive sports, have specific types of knee instability, or loose ligaments might be suitable candidates. As an unphased trial, this study allows participants to contribute to innovative research that could enhance future knee treatments.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Studies have shown that adding a lateral extra-articular tenodesis (LET) to anterior cruciate ligament reconstruction (ACLR) is generally safe, with a low rate of complications. Most side effects are rare and mild. In one study, 86% of patients returned to their previous level of sports activity after surgery. Other research found no increase in negative effects when LET was added to ACLR, suggesting that patients tolerate the treatment well. However, some patients might experience knee pain on the side where the surgery was performed. Overall, current data indicate that combining LET and ACLR is a safe option for those considering the procedure.12345
Why are researchers excited about this trial?
Researchers are excited about the ACL + LET treatment because it adds a lateral extra-articular tenodesis (LET) to the traditional ACL reconstruction. This additional step aims to provide extra stability to the knee, potentially reducing the risk of re-injury. Unlike the standard ACL reconstruction alone, this combined approach targets both the ACL and the structures on the outer side of the knee, which may enhance overall joint support. This could be particularly beneficial for athletes or active individuals who place high demands on their knees.
What evidence suggests that this trial's treatments could be effective for knee injuries?
Studies have shown that adding a procedure called lateral extra-articular tenodesis (LET) to anterior cruciate ligament reconstruction (ACLR) increases knee stability. In this trial, one group of participants will receive standard ACL reconstruction, while another group will receive ACL reconstruction with LET. Research indicates that this combination reduces the risk of knee instability by 38% and lowers the chance of ligament repair failure by 67%. These improvements occur because the procedure helps control the knee's twisting movements. Additionally, patients who underwent LET with ACLR reported better movement and function within seven months after surgery. However, there is some concern that LET might increase the long-term risk of developing osteoarthritis, a joint disease.13678
Are You a Good Fit for This Trial?
This trial is for individuals aged up to 25 with an ACL deficient knee, who play competitive pivoting sports and have a significant pivot shift in the knee or general ligament laxity. It's not suitable for those outside of these criteria.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo anterior cruciate ligament reconstruction (ACLR) with or without a lateral extraarticular tenodesis (LET)
Follow-up
Participants are monitored for the development of osteoarthritis and other outcomes using imaging and patient-reported outcomes over a 10-year period
What Are the Treatments Tested in This Trial?
Interventions
- ACL Reconstruction
- Lateral Extra-Articular Tenodesis (LET)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Western University, Canada
Lead Sponsor
Canadian Institutes of Health Research (CIHR)
Collaborator